Cannabis-derived medicines are recognised for their therapeutic effects. Firstly, they can contribute positively in the treatment of a wide range of diseases and disorders as multiple sclerosis (MS), seizures, HIV/AIDS, and mental disorders, amongst others, with their associated symptoms (including pain). Secondly, they are instrumental in relieving patients from the pain which can be induced by some of the treatment methods for various diseases including cancers. Yet, despite growing awareness and interest in medical cannabis within patient and medical communities, the regulatory framework for medical cannabis across the European Union remains fragmented. As a result of this lack of harmonisation, European patients suffer from serious difficulty in accessing high-quality cannabis-derived ;

On 13 February 2019, the European Parliament approved a motion for a resolution on medical cannabis, calling for a clear definition of medical cannabis and fair access to such treatments.

In this context, Member of the European Parliament (MEP) Guillaume Balas (FR, S&D), as well as Cannabis Europe invite you to attend the event “Ensuring fair access to medical cannabis for patients in Europe”.